MCID: ANG015
MIFTS: 54

Angioedema

Categories: Bone diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Oral diseases, Rare diseases, Skin diseases

Aliases & Classifications for Angioedema

MalaCards integrated aliases for Angioedema:

Name: Angioedema 12 74 54 6 43 15 17 71
Angioneurotic Oedema 12 32
Quincke's Edema 12 74
Angioneurotic Edema 12
Giant Urticaria 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1558
MeSH 43 D000799
NCIt 49 C112175
SNOMED-CT 67 41291007 82966003
ICD10 32 T78.3
UMLS 71 C0002994

Summaries for Angioedema

Disease Ontology : 12 A skin disease characterized by the rapid swelling of the dermis, subcutaneous tissue, mucosa and submucosal tissues.

MalaCards based summary : Angioedema, also known as angioneurotic oedema, is related to acquired angioedema and hereditary angioedema, and has symptoms including edema and peau d'orange. An important gene associated with Angioedema is F12 (Coagulation Factor XII), and among its related pathways/superpathways are Collagen chain trimerization and Peptide hormone metabolism. The drugs Enalaprilat and Enalapril have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and tongue, and related phenotype is behavior/neurological.

Wikipedia : 74 Angioedema is an area of swelling of the lower layer of skin and tissue just under the skin or mucous... more...

Related Diseases for Angioedema

Diseases in the Angioedema family:

Angioedema, Hereditary, Type I Angioedema, Hereditary, Type Iii
Hereditary Angioedema Acquired Angioedema
Acquired Angioedema Type 1 Acquired Angioedema Type 2

Diseases related to Angioedema via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 529)
# Related Disease Score Top Affiliating Genes
1 acquired angioedema 34.8 SERPING1 C1S
2 hereditary angioedema 34.4 XPNPEP2 SERPING1 KNG1 KLKB1 F12 C1S
3 non-histaminic angioedema 34.4 SYTL2 F12
4 c1 inhibitor deficiency 33.6 SERPING1 KNG1 KLKB1 F12 C1S BDKRB2
5 hydrops, lactic acidosis, and sideroblastic anemia 31.5 SERPING1 PTGS2 PTGS1 KNG1 C1S
6 physical urticaria 31.2 SERPING1 KNG1 HRH1
7 cholinergic urticaria 31.0 SERPING1 HRH1
8 allergic hypersensitivity disease 31.0 KNG1 IL5 IGHE HRH1
9 food allergy 30.9 IL5 IGHE HRH1
10 allergic urticaria 30.9 SERPING1 KNG1
11 drug allergy 30.9 IL5 IGHE ACE
12 urticaria 30.6 SERPING1 PTGS2 PTGS1 LTC4S IL5 IGHE
13 end stage renal failure 30.5 PTGS2 BDKRB2 AGTR2 ACE
14 allergic rhinitis 30.4 KNG1 IL5 IGHE HRH1
15 rhinitis 30.3 PTGS1 KNG1 IL5 IGHE HRH1
16 proteasome-associated autoinflammatory syndrome 1 30.2 PTGS2 PTGS1 IL5
17 conjunctivitis 30.2 IL5 IGHE HRH1
18 gastroesophageal reflux 30.2 PTGS2 PTGS1 IL5
19 dermatitis, atopic 29.8 KNG1 IL5 IGHE HRH1 DPP4
20 cardiovascular system disease 29.6 PTGS2 PTGS1 MME KNG1 AGTR2 ACE
21 myocardial infarction 29.2 SERPING1 PTGS2 PTGS1 MME KNG1 DPP4
22 asthma 29.2 PTGS1 MME LTC4S KNG1 IL5 IGHE
23 hypertension, essential 29.0 PTGS2 PTGS1 MME KNG1 KLKB1 F12
24 angioedema, hereditary, type i 12.8
25 angioedema, hereditary, type iii 12.8
26 angioedema induced by ace inhibitors 12.8
27 episodic angioedema with eosinophilia 12.6
28 hereditary angioedema with normal c1inh 12.3
29 hereditary angioedema with c1inh deficiency 12.2
30 acquired angioedema type 1 12.2
31 acquired angioedema type 2 12.2
32 vibratory urticaria 12.2
33 plg-related hereditary angioedema with normal c1inh 12.1
34 angpt1-related hereditary angioedema with normal c1inh 12.1
35 acquired angioedema with c1inh deficiency 12.1
36 complement component 4, partial deficiency of 11.7
37 cold urticaria 11.5
38 loiasis 11.5
39 carboxypeptidase n deficiency 11.4
40 netherton syndrome 11.2
41 hypereosinophilic syndrome 10.6
42 melkersson-rosenthal syndrome 10.6 SERPING1 ACE
43 fissured tongue 10.5 SERPING1 ACE
44 familial vesicoureteral reflux 10.5 AGTR2 ACE
45 malignant essential hypertension 10.5 KNG1 KLKB1 ACE
46 exanthem 10.5
47 pyruvate kinase deficiency of red cells 10.5 KNG1 KLKB1 BDKRB2
48 posterior urethral valves 10.5 AGTR2 ACE
49 cefuroxime allergy 10.5 PTGS2 IL5
50 aspirin resistance 10.5 PTGS2 PTGS1

Graphical network of the top 20 diseases related to Angioedema:



Diseases related to Angioedema

Symptoms & Phenotypes for Angioedema

UMLS symptoms related to Angioedema:


edema, peau d'orange

MGI Mouse Phenotypes related to Angioedema:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.4 ACE AGTR2 BDKRB2 CPN1 HNMT HRH1

Drugs & Therapeutics for Angioedema

Drugs for Angioedema (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 260)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Enalaprilat Approved Phase 4 76420-72-9 6917719
2
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
3
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
4
Methadone Approved Phase 4 76-99-3 4095
5
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
6
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 161973-10-0, 119141-88-7 9568614 4594
7
Azithromycin Approved Phase 4 83905-01-5 55185 447043
8
Ethanol Approved Phase 4 64-17-5 702
9
Ramipril Approved Phase 4 87333-19-5 5362129
10
Fexofenadine Approved, Investigational Phase 4 83799-24-0 3348
11
Desloratadine Approved, Investigational Phase 4 100643-71-8 124087
12
Ebastine Approved, Investigational Phase 4 90729-43-4 3191
13
Budesonide Approved Phase 4 51333-22-3 63006 5281004
14
Omalizumab Approved, Investigational Phase 4 242138-07-4
15
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
16
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
17
Ofloxacin Approved Phase 4 82419-36-1 4583
18
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
19
Icatibant Approved, Investigational Phase 4 130308-48-4, 138614-30-9 71364
20
Cysteine Approved, Nutraceutical Phase 4 52-90-4 5862
21
Lactitol Investigational Phase 4 585-86-4, 585-88-6 493591
22
Bradykinin Investigational Phase 4 58-82-2 439201
23 Antiviral Agents Phase 4
24 Protective Agents Phase 4
25 Antioxidants Phase 4
26 N-monoacetylcystine Phase 4
27 Narcotics Phase 4
28 Free Radical Scavengers Phase 4
29 Antitussive Agents Phase 4
30 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
31 Antidotes Phase 4
32 Expectorants Phase 4
33 Proton Pump Inhibitors Phase 4
34 Anti-Ulcer Agents Phase 4
35 Antacids Phase 4
36 Anti-Inflammatory Agents Phase 4
37 Hormones Phase 4
38 Hormone Antagonists Phase 4
39 Histamine H1 Antagonists, Non-Sedating Phase 4
40 glucocorticoids Phase 4
41 Cholinergic Agents Phase 4
42 Cholinergic Antagonists Phase 4
43 Bronchodilator Agents Phase 4
44 Respiratory System Agents Phase 4
45 Anti-Asthmatic Agents Phase 4
46 Rho(D) Immune Globulin Phase 4
47 Immunoglobulins, Intravenous Phase 4
48 gamma-Globulins Phase 4
49 Antibiotics, Antitubercular Phase 4
50 Renal Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 190)
# Name Status NCT ID Phase Drugs
1 A Clinical Study on Anti-Hypertensive Agent (ACEi) and Heart Function Improvement Unknown status NCT01069042 Phase 4 Enalapril
2 The Safety and Immunogenicity Study of Rotavirus Vaccine Simultaneously Vaccinated With MR or MMR Vaccine Unknown status NCT02153866 Phase 4
3 Evaluation Whether Higher Retention Rate is in Those of Combined Methadone With N-Acetyl-Cysteine Compared to Those With Methadone Alone During a Six-month Study Unknown status NCT01047956 Phase 4 Methadone; NAC;Methadone
4 Open Label, Multicenter Study to Evaluate Efficacy, Safety and Tolerability of a Self-Administered Subcutaneous Formulation of Icatibant for the Treatment of Acute Attacks of Hereditary Angioedema (IHA) Completed NCT01457430 Phase 4 Icatibant
5 Hereditary Angioedema : Interest From the Use of a Call Center During the Attacks. Completed NCT01679912 Phase 4
6 A Prospective, Randomized, Placebo-controlled Trial of Pre-transplant and Prompt Post-transplant Treatment With Azithromycin to Improve Early Allograft Function and Outcome After Lung Transplantation Completed NCT01915082 Phase 4 Azithromycin;Ora-Plus
7 Prospective Open-label Uncontrolled Multi-center Post-marketing Study to Assess Inhibitory Antibody Formation in Subjects With Congenital C1-INH Deficiency and Acute Hereditary Angioedema (HAE) Attacks Treated With Berinert® , a C1-esterase Inhibitor Completed NCT01467947 Phase 4
8 A Phase 4 Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE® (C1 Inhibitor [Human]) as Prophylactic Therapy in Subjects With Inadequately Controlled Hereditary Angioedema Attacks Completed NCT00914966 Phase 4
9 Effects of Esomeprazole on Gastric Emptying of Alcoholic Beverages, Blood Alcohol Concentrations, Gastroesophageal Reflux and Release of Some Gastrointestinal Hormones in Healthy Volunteers Completed NCT00472550 Phase 4 esomeprazole 20 mg
10 A Dose Escalation, Randomized, Double-blind Withdrawal Study of the Efficacy, Dose-response, and Safety of Ramipril for the Treatment of Hypertension in Children and Adolescents Completed NCT00044265 Phase 4 ramipril
11 Evaluation of the Inhibitory Effect of 5 Anti-Histamines in Urticaria Completed NCT01940393 Phase 4 Cetirizine;Desloratadine;Fexofenadine;Ebastine;Bilastine
12 Nasal Budesonide in Children With Rhinitis and/or Mild Obstructive Sleep Apnea Syndrome Completed NCT00560586 Phase 4 Budesonide;placebo
13 A Phase IV, Randomized, Double-Blind, Placebo-Controlled Exploratory Study of Xolair (Omalizumab) for Treatment of Idiopathic Angioedema in Patients Who Remain Symptomatic Despite Current Therapy Recruiting NCT02966314 Phase 4 Omalizumab;Placebos
14 A Single-site, Open-Label, Pilot Study to Evaluate the Benefit of RUCONEST® in Subjects Who Experience ADRs Related to IVIG Infusions Recruiting NCT03576469 Phase 4
15 Randomized Trial of Short Antibiotic Course to Decrease Post ERCP Cholangitis Recruiting NCT03087656 Phase 4 Ceftriaxone;Levofloxacin
16 The Effect of Local Infiltration of Liposomal Bupivacaine on Opioid Consumption at Time of Cesarean Delivery: A Randomized Controlled Trial Not yet recruiting NCT03907813 Phase 4 Exparel
17 Effect of Bradykinin Receptor Antagonism on ACE Inhibitor-associated Angioedema - a Mulitcenter Trial Terminated NCT01574248 Phase 4 icatibant
18 Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Determine the Efficacy of 1000u, and 1500u of C1-INH Compared to Placebo at the Time of Prodromal Symptoms in Preventing an Acute HAE Exacerbation. Withdrawn NCT01151735 Phase 4 C-1-esterase;C-1-esterase;placebo
19 Intravenous Versus Oral Regimens of Dexamethasone for Prophylaxis of Paclitaxel-associated Hypersensitivity Reaction in Primary Ovarian, Fallopian Tube and Peritoneal Cancer Patients: a Double-blind Randomized Controlled Trial Unknown status NCT02349763 Phase 3 Intravenous Dexamethasone;Oral Dexamethasone
20 A Prospective Randomized Comparative Study of Efficacy and Safety of Combined Deferiprone (DFP) and Deferasirox Versus DFP and Desferrioxamine (DFO) Therapy in Diseases With Severe Iron Overload Unknown status NCT01511848 Phase 2, Phase 3 DFP (ferriprox) and deferasirox (ICL 670);DFP, DFO
21 Pharmacokinetics, Clinical Efficacy and Safety of C1 Inhibitor Concentrate (C1-Esteraseremmer-N) for the Treatment of Hereditary (and Acquired) Angioedema Completed NCT00125151 Phase 3 C1 inhibitor concentrate (C1-esteraseremmer-N)
22 Pharmacokinetics, Clinical Efficacy and Safety of C1 Inhibitor Concentrate (C1-Esteraseremmer-N) for the Treatment of Hereditary (and Acquired) Angioedema Completed NCT00125541 Phase 2, Phase 3 C1 inhibitor concentrate (C1-esteraseremmer-N)
23 An Open-Label Study of Icatibant in Japanese Subjects With Acute Attacks of Hereditary Angioedema. Completed NCT03888755 Phase 3 Icatibant
24 LEVP2006-4 CHANGE 3 Trial (C1-Inhibitor in Hereditary Angioedema Nanofiltration Generation Evaluating Efficacy): Open-Label Use of C1INH-nf (Human) for the Prophylactic Treatment to Prevent HAE Attacks and as Treatment in Acute HAE Attacks Completed NCT00462709 Phase 3
25 A Randomized, Placebo-controlled, Double-blind Phase III Study of the Efficacy and Safety of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema Completed NCT00262301 Phase 3 recombinant human C1 inhibitor;Placebo
26 A Phase 3, Multicenter, Randomized, Single-Blind, Dose-Ranging, Crossover Study to Evaluate the Safety and Efficacy of Intravenous Administration of CINRYZE® (C1 Esterase Inhibitor [Human]) for the Prevention of Angioedema Attacks in Children 6 to 11 Years of Age With Hereditary Angioedema Completed NCT02052141 Phase 3
27 A Randomized, Placebo-controlled, Double Blind Phase II/III Study of the Safety and Efficacy of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema Completed NCT00225147 Phase 2, Phase 3 Recombinant Human C1 Inhibitor;placebo
28 A Phase 3, Randomized, Double-blind, Placebo-controlled, Two-period, Three-sequence, Partial Crossover Study to Evaluate the Efficacy and Safety of Subcutaneous Administration of 2000 IU of C1 Esterase Inhibitor [Human] Liquid for Injection for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema Completed NCT02584959 Phase 3 C1 esterase inhibitor [human] liquid;Placebo
29 A Phase II/III Study of the Efficacy and Safety of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema Completed NCT00262288 Phase 2, Phase 3 i.v. recombinant human C1 inhibitor
30 A Phase 3, Open-label, Single-period Study to Evaluate the Safety and Treatment Effect of Intravenous Administration of C1 Inhibitor (Human) for the Prevention of Angioedema Attacks and Treatment of Breakthrough Attacks in Japanese Subjects With Hereditary Angioedema (HAE) Completed NCT02865720 Phase 3 CINRYZE 500 U;CINRYZE 1000 U
31 A Double-blind, Randomized, Placebo-controlled, Cross-over Study to Evaluate the Clinical Efficacy and Safety of Subcutaneous Administration of Human Plasma-derived C1-esterase Inhibitor in the Prophylactic Treatment of Hereditary Angioedema Completed NCT01912456 Phase 3
32 OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema Completed NCT02303626 Phase 2, Phase 3 BCX4161;Placebo
33 A Phase III Randomized, Double-blind, Placebo-controlled Study With an Open-label Extension Evaluating the Efficacy, Safety and Immunogenicity of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks of Angioedema in Patients With HAE Completed NCT01188564 Phase 3 rhC1INH;Placebo (Saline)
34 A Double-blind, Placebo-controlled Study (72 Patients, Randomized 1:1) Followed by a Repeat-dosing Phase to Assess the Efficacy and Safety of DX-88 (Ecallantide; Recombinant Plasma Kallikrein Inhibitor) for the Treatment of Acute Attacks of Hereditary Angioedema Completed NCT00262080 Phase 3 ecallantide;Phosphate Buffer Saline (PBS),
35 LEVP2006-1 CHANGE 2 Trial (C1-Inhibitor in Hereditary Angioedema Nanofiltration Generation Evaluating Efficacy): Open-Label Safety/Efficacy Repeat Exposure Study of C1INH-nf (Human) in the Treatment of Acute HAE Attacks Completed NCT00438815 Phase 3
36 Open-label Extension Study of CE1145 (Human Pasteurized C1 Esterase Inhibitor Concentrate) in Subjects With Congenital C1-INH Deficiency and Acute HAE Attacks Completed NCT00292981 Phase 3 C1 Esterase Inhibitor
37 EDEMA4: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of DX-88 (Ecallantide) for the Treatment of Acute Attacks of Hereditary Angioedema Completed NCT00457015 Phase 3 ecallantide;Phosphate Buffer Saline (PBS), pH 7.0
38 Open-label Patient Continuation of DX-88 (Ecallantide) for Acute Hereditary Angioedema Attacks Completed NCT00456508 Phase 3 ecallantide
39 Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Study Evaluating the Safety & Efficacy of Icatibant as a Treatment for Angiotensin-Converting Enzyme Inhibitor (ACE-I)-Induced Angioedema in Adults Completed NCT01919801 Phase 3 Icatibant;Placebo
40 Pharmacokinetics Berinert P Study of Subcutaneous Versus Intravenous Administration in Subjects With Moderate Hereditary Angioedema - The Passion Study Completed NCT00748202 Phase 3 C1-Esterase Inhibitor
41 Randomized, Double Blind, Placebo-Controlled, Multicenter Study of a Subcutaneous Formulation of Icatibant for the Treatment of Hereditary Angioedema Completed NCT00097695 Phase 3 Icatibant;Placebo
42 An Open-label, Randomized Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneous Administration of Human Plasma-derived C1-esterase Inhibitor in the Prophylactic Treatment of Hereditary Angioedema Completed NCT02316353 Phase 3
43 HELP Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate DX-2930 For Long-Term Prophylaxis Against Acute Attacks of Hereditary Angioedema (HAE) Completed NCT02586805 Phase 3 DX-2930 - 300mg/2wk;DX-2930 - 300mg/4wk;DX-2930 - 150mg/4wk;Placebo
44 A Randomized, Double-blind, Placebo-controlled, 28-week Treatment With a 8 Week Follow-up to Investigate the Impact of Omalizumab on Quality of Life Measures and the Incidence and Severity of Angioedema Despite H1-antihistamine Therapy. Completed NCT01723072 Phase 3 Placebo
45 HELP Study ExtensionTM: An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of DX-2930 for Prevention Against Acute Attacks of Hereditary Angioedema (HAE) Completed NCT02741596 Phase 3 DX-2930;DX-2930
46 LEVP2005-1/Part B: A Double-blind, Placebo-Controlled, Clinical Study to Investigate the Efficacy and Safety of Purified C1 Esterase Inhibitor (Human) as Prophylactic Treatment to Prevent HAE Attacks Completed NCT01005888 Phase 3 Placebo (saline)
47 Open Label, Multicenter Study to Evaluate Safety, Local Tolerability, Convenience, and Efficacy of a Self-Administered Subcutaneous Formulation of Icatibant for the Treatment of Acute Attacks of Hereditary Angioedema Completed NCT00997204 Phase 3 Icatibant
48 LEVP2005-1/Part A: A Double-blind, Placebo-Controlled, Clinical Study to Investigate the Efficacy and Safety of Purified C1 Esterase Inhibitor (Human) for the Treatment of HAE in Acute Attacks Completed NCT00289211 Phase 3 Placebo (saline)
49 A Phase III Randomized, Double-Blind,Placebo-Controlled, Multicenter Study of Icatibant for Subcutaneous Injection in Patients With Acute Attacks of Hereditary Angioedema (HAE) Completed NCT00912093 Phase 3 Icatibant;Placebo
50 Randomised Double Blind, Controlled, Parallel Group, Multicentre Study of a Subcutaneous Formulation of Icatibant Versus Oral Tranexamic Acid for the Treatment of Hereditary Angioedema (HAE) Completed NCT00500656 Phase 3 Icatibant;Tranexamic Acid;Oral Placebo;S.C. Placebo

Search NIH Clinical Center for Angioedema

Inferred drug relations via UMLS 71 / NDF-RT 50 :


carbinoxamine
Carbinoxamine maleate
Fluoxymesterone

Cochrane evidence based reviews: angioedema

Genetic Tests for Angioedema

Anatomical Context for Angioedema

MalaCards organs/tissues related to Angioedema:

40
Skin, Testes, Tongue, Heart, Thyroid, Liver, Kidney

Publications for Angioedema

Articles related to Angioedema:

(show top 50) (show all 5919)
# Title Authors PMID Year
1
[Emergency management of acute angioedema]. 54 61
20461661 2010
2
Advances in basic and clinical immunology in 2009. 54 61
20226292 2010
3
[Angioedema during ACE and DPP-4 inhibition]. 54 61
20196430 2010
4
Allergic reaction related to ramipril use: a case report. 54 61
20180980 2010
5
Kinins, airway obstruction, and anaphylaxis. 54 61
20519882 2010
6
Increased total and mite-specific immunoglobulin E in patients with aspirin-induced urticaria and angioedema. 54 61
20461968 2010
7
Acute abdomen due to intestinal angioedema induced by ACE inhibitors: not so rare? 54 61
20163043 2009
8
Angiotensin-converting enzyme and dipeptidyl peptidase IV inhibitors: an increased risk of angioedema. 54 61
19581503 2009
9
Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema. 54 61
19581505 2009
10
[Anaesthesic management of vaginal delivery in a parturient with C1 esterase deficiency]. 54 61
19359129 2009
11
Genetic analysis of Factor XII and bradykinin catabolic enzymes in a family with estrogen-dependent inherited angioedema. 54 61
19178938 2009
12
Nonallergic hypersensitivity to nonsteroidal antiinflammatory drugs, angiotensin-converting enzyme inhibitors, radiocontrast media, local anesthetics, volume substitutes and medications used in general anesthesia. 54 61
19386216 2009
13
Angiotensin converting enzyme inhibitors and delayed onset, recurrent angioedema of the head and neck. 54 61
19023310 2008
14
Angioedema after local trauma in a patient on angiotensin-converting enzyme inhibitor therapy. 54 61
18988727 2008
15
[Angiotensin-converting enzyme inhibitor-related angioedema: emergency treatment with complement C1 inhibitor concentrate]. 54 61
18096274 2008
16
Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors. 54 61
18413488 2008
17
Endoscopic visualization of angiotensin-converting enzyme inhibitor-induced small bowel angioedema as a cause of relapsing abdominal pain using double-balloon enteroscopy. 54 61
18320317 2008
18
The role of ace gene polymorphism in the development of angioedema secondary to angiotensin converting enzyme inhibitors and angiotensin II receptor blockers. 54 61
18680700 2008
19
[Orolingual angioedema as complication after rt-PA in stroke patient treated with ACE inhibitor]. 54 61
18453163 2008
20
Pediatric angioedema. 54 61
18330729 2008
21
Potential role of vasomotor effects of fibrinogen in bradykinin-induced angioedema. 54 61
18395553 2008
22
New treatments addressing the pathophysiology of hereditary angioedema. 54 61
18410689 2008
23
[The multiple etiologies of angioedema]. 54 61
18557532 2008
24
Aliskiren as an alternative in a patient with life-threatening ACE inhibitor-induced angioedema. 54 61
18295074 2008
25
Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema. 54 61
18084312 2008
26
[Orolingual angioedema secondary to alteplase treatment in cases of stroke]. 54 61
18368687 2008
27
Metallopeptidase activities in hereditary angioedema: effect of androgen prophylaxis on plasma aminopeptidase P. 54 61
18158172 2008
28
Is dipeptidylpeptidase IV the missing link in angiotensin-converting enzyme inhibitor--induced angioedema? 54 61
18025291 2008
29
Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor associated angioedema. 54 61
18025295 2008
30
[Angioedema]. 54 61
18004529 2007
31
Clinical experience with angiotensin-converting enzyme inhibitor-induced angioedema. 54 61
18036423 2007
32
Differential contribution of the CysLTR1 gene in patients with aspirin hypersensitivity. 54 61
17641958 2007
33
Anti-cholesterol antibody levels in hereditary angioedema. 54 61
18205707 2007
34
[ACE-inhibitor induced angioedema]. 54 61
17966084 2007
35
[Are AT1 receptor antagonists an alternative to ACE inhibitors in angioedema?]. 54 61
18062333 2007
36
Not all ACE inhibitor related angioedema is always evident: a case which is misdiagnosed as panic attack and speech disorder. 54 61
18047821 2007
37
[Angioneurotic edema of the head and neck in association with ACE inhibitors]. 54 61
17333046 2007
38
Nonallergic angioedema: role of bradykinin. 54 61
17620062 2007
39
Safety of celecoxib in patients with cutaneous reactions due to ASA-NSAIDs intolerance. 54 61
17663920 2007
40
[Iatrogenic angioedema: the role of angiotensin converting enzyme inhibitor and angiotensin II receptor blockers]. 54 61
17540310 2007
41
[Angioedema caused by C1-esterase inhibitor deficiency or ACE inhibitors?]. 54 61
17356860 2007
42
Safety of selective cyclooxygenase-2 inhibitors and a basic non-steroidal anti-inflammatory drug (NSAID) in Japanese patients with NSAID-induced urticaria and/or angioedema: Comparison of meloxicam, etodolac and tiaramide. 54 61
17291297 2007
43
Olmesartan medoxomil-induced angioedema. 54 61
17341528 2007
44
Anaphylactoid reaction to recombinant tissue plasminogen activator. 54 61
17198333 2007
45
Cutaneous adverse effects of angiotensin-II receptor antagonists. 54 61
17326283 2007
46
Acute upper airway obstruction from acquired angioedema. 54 61
17305664 2007
47
Laboratory testing for C1 inhibitor deficiency: a comparison of two approaches to C1 inhibitor function. 54 61
17270096 2007
48
Angiotensin-converting enzyme (ACE) inhibitor-associated angioedema of the stomach and small intestine: a case report. 54 61
17285209 2006
49
First case of homozygous C1 inhibitor deficiency. 54 61
17137866 2006
50
Angiotensin-converting enzyme inhibitor-associated angioedema. 54 61
17085287 2006

Variations for Angioedema

ClinVar genetic disease variations for Angioedema:

6 ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 F12 NM_000505.3(F12):c.983C>G (p.Thr328Arg)SNV Pathogenic 1170 rs118204456 5:176831232-176831232 5:177404231-177404231
2 SYTL2 NM_032943.4(SYTL2):c.890del (p.Ser297fs)deletion Pathogenic 375385 rs1057519445 11:85445479-85445479 11:85734436-85734436
3 SERPING1 NM_000062.2(SERPING1):c.1475T>C (p.Met492Thr)SNV Likely pathogenic 427759 rs978962357 11:57382026-57382026 11:57614553-57614553
4 SERPING1 NM_000062.3(SERPING1):c.51+1deldeletion Likely pathogenic 689535 11:57365792-57365792 11:57598319-57598319
5 SERPING1 NM_000062.3(SERPING1):c.369C>G (p.Cys123Trp)SNV Uncertain significance 689536 11:57367669-57367669 11:57600196-57600196
6 SERPING1 NM_000062.3(SERPING1):c.1249+5G>CSNV Uncertain significance 689537 11:57379414-57379414 11:57611941-57611941

Expression for Angioedema

Search GEO for disease gene expression data for Angioedema.

Pathways for Angioedema

Pathways related to Angioedema according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.46 XPNPEP2 MME KNG1 KLKB1 F12 DPP4
2
Show member pathways
11.97 MME DPP4 CPN1 ACE
3
Show member pathways
11.82 SERPING1 KNG1 KLKB1 F12
4
Show member pathways
11.7 PTGS2 PTGS1 LTC4S
5
Show member pathways
11.26 MME KNG1 BDKRB2 AGTR2 ACE
6 11.26 SERPING1 KNG1 KLKB1 F12 C1S BDKRB2
7 11.23 SERPING1 KLKB1 F12
8 10.76 PTGS2 PTGS1
9 10.71 PTGS2 PTGS1 LTC4S
10 10.61 PTGS2 PTGS1

GO Terms for Angioedema

Cellular components related to Angioedema according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.03 XPNPEP2 SYTL2 MME KNG1 KLKB1 IGHE
2 extracellular space GO:0005615 9.76 SERPING1 KNG1 KLKB1 IL5 F12 CPN1
3 extracellular exosome GO:0070062 9.65 XPNPEP2 SERPING1 PTGS1 MME KNG1 KLKB1
4 extracellular region GO:0005576 9.36 XPNPEP2 SERPING1 KNG1 KLKB1 IL5 IGHE

Biological processes related to Angioedema according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 blood coagulation GO:0007596 9.8 SERPING1 KNG1 KLKB1 F12
2 regulation of complement activation GO:0030449 9.78 SERPING1 CPN1 C1S
3 proteolysis GO:0006508 9.76 XPNPEP2 MME KLKB1 F12 DPP4 CPN1
4 cellular oxidant detoxification GO:0098869 9.72 PTGS2 PTGS1 LTC4S
5 response to glucocorticoid GO:0051384 9.69 PTGS2 HNMT CPN1
6 regulation of blood pressure GO:0008217 9.62 PTGS2 PTGS1 AGTR2 ACE
7 zymogen activation GO:0031638 9.6 KLKB1 F12
8 lipoxygenase pathway GO:0019372 9.59 PTGS2 LTC4S
9 prostaglandin biosynthetic process GO:0001516 9.58 PTGS2 PTGS1
10 amyloid-beta metabolic process GO:0050435 9.58 MME ACE
11 fibrinolysis GO:0042730 9.58 SERPING1 KLKB1 F12
12 peptide metabolic process GO:0006518 9.57 MME CPN1
13 angiotensin maturation GO:0002003 9.56 MME ACE
14 hemostasis GO:0007599 9.56 SERPING1 KNG1 KLKB1 F12
15 regulation of vascular permeability GO:0043114 9.54 HRH1 BDKRB2
16 vasodilation GO:0042311 9.54 KNG1 BDKRB2 AGTR2
17 cyclooxygenase pathway GO:0019371 9.52 PTGS2 PTGS1
18 negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stress GO:1902219 9.48 PTGS2 BDKRB2
19 positive regulation of fibrinolysis GO:0051919 9.46 KLKB1 F12
20 Factor XII activation GO:0002542 9.43 KLKB1 F12
21 blood coagulation, intrinsic pathway GO:0007597 9.26 SERPING1 KNG1 KLKB1 F12
22 inflammatory response GO:0006954 9.23 PTGS2 PTGS1 KNG1 KLKB1 IL5 HRH1

Molecular functions related to Angioedema according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hydrolase activity GO:0016787 10.01 XPNPEP2 MME KLKB1 F12 DPP4 CPN1
2 metallopeptidase activity GO:0008237 9.62 XPNPEP2 MME CPN1 ACE
3 serine-type endopeptidase activity GO:0004252 9.56 KLKB1 F12 DPP4 C1S
4 serine-type peptidase activity GO:0008236 9.46 KLKB1 F12 DPP4 C1S
5 dipeptidyl-peptidase activity GO:0008239 9.43 DPP4 ACE
6 exopeptidase activity GO:0008238 9.37 MME ACE
7 peptidase activity GO:0008233 9.23 XPNPEP2 MME KLKB1 F12 DPP4 CPN1
8 prostaglandin-endoperoxide synthase activity GO:0004666 8.96 PTGS2 PTGS1

Sources for Angioedema

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....